Bcl‐xL represents a therapeutic target in Philadelphia negative myeloproliferative neoplasms

Myeloproliferative neoplasms are divided into essential thrombocythemia (ET), polycythemia vera (PV) and primary myelofibrosis (PMF). Although ruxolitinib was proven to be effective in reducing symptoms, patients rarely achieve complete molecular remission. Therefore, it is relevant to identify new...

Descripción completa

Detalles Bibliográficos
Autores principales: Petiti, Jessica, Lo Iacono, Marco, Rosso, Valentina, Andreani, Giacomo, Jovanovski, Aleksandar, Podestà, Marina, Lame, Dorela, Gobbi, Marco De, Fava, Carmen, Saglio, Giuseppe, Frassoni, Francesco, Cilloni, Daniela
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7521327/
https://www.ncbi.nlm.nih.gov/pubmed/32790151
http://dx.doi.org/10.1111/jcmm.15730

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7521327/
https://www.ncbi.nlm.nih.gov/pubmed/32790151
http://dx.doi.org/10.1111/jcmm.15730

Ejemplares similares